Source:http://linkedlifedata.com/resource/pubmed/id/17632587
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2007-7-16
|
| pubmed:abstractText |
The radial artery (RA) is used as a spastic coronary bypass graft. This study was designed to investigate the mechanism of vasorelaxant effects of YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole), a nitric oxide (NO)-independent soluble guanylate cyclase (sGC) activator, and DEA/NO (diethylamine/nitric oxide), a NO-nucleophile adduct, on the human RA. RA segments (n = 25) were obtained from coronary artery bypass grafting patients and were divided into 3-4 mm vascular rings. Using the isolated tissue bath technique, the endothelium-independent vasodilatation function was tested in vitro by the addition of cumulative concentrations of YC-1 (10-10 to 3 x 10-7 mol/L) and DEA/NO (10-8 to 3 x 10-5 mol/L) following vasocontraction by phenylephrine in the presence or absence of 10-5 mol/L ODQ (1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one), the selective sGC inhibitor, 10-7 mol/L iberiotoxin, a blocker of Ca2+-activated K+ channels, or 10-5 mol/L ODQ plus 10-7 mol/L iberiotoxin. We also evaluated the effect of YC-1 and DEA/NO on the cGMP levels in vascular rings obtained from human radial artery (n = 6 for each drug). YC-1 (10-10 to 3 x 10-7 mol/L) and DEA/NO (10-8 to 3 x 10-5 mol/L) caused the concentration-dependent vasorelaxation in RA rings precontracted with phenylephrine (10-5 mol/L) (n = 20 for each drug). Pre-incubation of RA rings with ODQ, iberiotoxin, or ODQ plus iberiotoxin significantly inhibited the vasorelaxant effect of YC-1, but the inhibitor effect of ODQ plus iberiotoxin was significantly more than that of ODQ and iberiotoxin alone (p < 0.05). The vasorelaxant effect of DEA/NO almost completely abolished in the presence of ODQ and iberiotoxin plus ODQ, but did not significantly change in the presence of iberiotoxin alone (p > 0.05). The pEC50 value of DEA/NO was significantly lower than those for YC-1 (p < 0.01), with no change Emax values in RA rings. In addition, YC-1-stimulated RA rings showed more elevation in cGMP than that of DEA/NO (p < 0.05). These findings indicate that YC-1 is a more potent relaxant than DEA/NO in the human RA. The relaxant effects of YC-1 could be due to the stimulation of the sGC and Ca2+-sensitive K+channels, whereas the relaxant effects of DEA/NO could be completely due to the stimulation of the sGC. YC-1 and DEA/NO may be effective as vasodilator for the short-term treatment of perioperative spasm of coronary bypass grafts.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1,1-diethyl-2-hydroxy-2-nitrosohydra...,
http://linkedlifedata.com/resource/pubmed/chemical/1H-(1,2,4)oxadiazolo(4,3-a)quinoxali...,
http://linkedlifedata.com/resource/pubmed/chemical/3-(5'-hydroxymethyl-2'-furyl)-1-benz...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic GMP,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Activators,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Hydrazines,
http://linkedlifedata.com/resource/pubmed/chemical/Indazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Donors,
http://linkedlifedata.com/resource/pubmed/chemical/Oxadiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Phenylephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Potassium Channels...,
http://linkedlifedata.com/resource/pubmed/chemical/Quinoxalines,
http://linkedlifedata.com/resource/pubmed/chemical/Vasoconstrictor Agents,
http://linkedlifedata.com/resource/pubmed/chemical/iberiotoxin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0008-4212
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
85
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
521-6
|
| pubmed:dateRevised |
2009-11-3
|
| pubmed:meshHeading |
pubmed-meshheading:17632587-Aged,
pubmed-meshheading:17632587-Analysis of Variance,
pubmed-meshheading:17632587-Coronary Artery Bypass,
pubmed-meshheading:17632587-Cyclic GMP,
pubmed-meshheading:17632587-Dose-Response Relationship, Drug,
pubmed-meshheading:17632587-Enzyme Activators,
pubmed-meshheading:17632587-Enzyme Inhibitors,
pubmed-meshheading:17632587-Female,
pubmed-meshheading:17632587-Humans,
pubmed-meshheading:17632587-Hydrazines,
pubmed-meshheading:17632587-Indazoles,
pubmed-meshheading:17632587-Male,
pubmed-meshheading:17632587-Middle Aged,
pubmed-meshheading:17632587-Nitric Oxide Donors,
pubmed-meshheading:17632587-Oxadiazoles,
pubmed-meshheading:17632587-Peptides,
pubmed-meshheading:17632587-Phenylephrine,
pubmed-meshheading:17632587-Potassium Channels, Calcium-Activated,
pubmed-meshheading:17632587-Quinoxalines,
pubmed-meshheading:17632587-Radial Artery,
pubmed-meshheading:17632587-Vasoconstrictor Agents,
pubmed-meshheading:17632587-Vasodilation
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.
|
| pubmed:affiliation |
Department of Cardiovascular Surgery, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey. oberkan@cumhuriyet.edu.tr
|
| pubmed:publicationType |
Journal Article,
In Vitro
|